Neuropsychological change in schizophrenia after 6 weeks of clozapine

被引:41
作者
Purdon, SE
Labelle, A
Boulay, L
机构
[1] Univ Alberta, Dept Psychiat, Edmonton, AB, Canada
[2] Univ Ottawa, Dept Psychiat, Ottawa, ON K1N 6N5, Canada
[3] Royal Ottawa Hosp, Schizophrenia Program, Ottawa, ON K1Z 7K4, Canada
[4] Carleton Univ, Ottawa, ON K1S 5B6, Canada
关键词
clozapine; cognition; neuroleptic; neuropsychology; schizophrenia;
D O I
10.1016/S0920-9964(00)00101-8
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Neuropsychological change after 6 weeks of clozapine treatment was examined in 18 treatment-refractory patients to test anticipated domain-specific cognitive improvements. The first aim of this study was to test the assumption that increased homogeneity of sample and treatment would yield an experimental design with sufficient sensitivity to detect general intellectual changes with clozapine that were not apparent in one previous investigation. The second aim was to test predictions derived from a domain-specific review of all other investigations with clozapine suggesting salient gains on tests sensitive to motor and mental speed, visual spatial manipulation, and new learning of verbal material. The results showed that the comprehensive neuropsychological test battery was sensitive to general cognitive changes with clozapine, and supported the hypothesized domain-specific gains on tests of motor and mental speed, visual spatial manipulation and new verbal learning. Novel gains were also apparent on tests of new learning with nonverbal material. The results are discussed in relation to aspects of experimental design necessary for the evaluation of prospective medication-induced changes in cognitive skill, particularly in future investigations designed to differentiate between second-generation antipsychotic medications. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:57 / 67
页数:11
相关论文
共 37 条
[1]   Neurocognitive impairment in schizophrenia and how it affects treatment options [J].
Bilder, RM .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1997, 42 (03) :255-264
[2]  
Bilder RM, 1994, PREDICTION NEUROLEPT, P99
[3]   COURSE OF ILLNESS AND PREDICTORS OF OUTCOME IN CHRONIC-SCHIZOPHRENIA - IMPLICATIONS FOR PATHOPHYSIOLOGY [J].
BREIER, A ;
SCHREIBER, JL ;
DYER, J ;
PICKAR, D .
BRITISH JOURNAL OF PSYCHIATRY, 1992, 161 :38-43
[4]  
BUCHANAN RW, 1994, ARCH GEN PSYCHIAT, V51, P804
[5]   NEUROLEPTICS - EFFECTS ON NEUROPSYCHOLOGICAL FUNCTION IN CHRONIC-SCHIZOPHRENIC PATIENTS [J].
CASSENS, G ;
INGLIS, AK ;
APPELBAUM, PS ;
GUTHEIL, TG .
SCHIZOPHRENIA BULLETIN, 1990, 16 (03) :477-499
[6]  
CHOUINARD G, 1980, CAN J NEUROL SCI, V7, P233
[7]   Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs [J].
Gallhofer, B ;
Bauer, U ;
Lis, S ;
Krieger, S ;
Gruppe, H .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1996, 6 :13-20
[8]   THE EFFECT OF CLOZAPINE ON COGNITION AND PSYCHIATRIC-SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA [J].
GOLDBERG, TE ;
GREENBERG, RD ;
GRIFFIN, SJ ;
GOLD, JM ;
KLEINMAN, JE ;
PICKAR, D ;
SCHULZ, SC ;
WEINBERGER, DR .
BRITISH JOURNAL OF PSYCHIATRY, 1993, 162 :43-48
[9]  
Green MF, 1997, AM J PSYCHIAT, V154, P799
[10]  
Green MF, 1996, AM J PSYCHIAT, V153, P321